A phase I/II trial of MEK162 in combination with gemcitabine (G) and cisplatin (C) for patients (pts) with untreated advanced biliary cancer (ABC).
Sign Up to like & getrecommendations! Published in 2017 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2017.35.4_suppl.290
Abstract: 290Background: Activating mutations in the RAS/RAF/MEK/ERK signaling pathway are commonly found in ABC. MEK162 is an oral, selective small molecule inhibitor of MEK1/2; single agent activity of MEK162 in ABC has previously been observed. Preclinical… read more here.
Keywords: phase; mek162 combination; trial mek162; abc ... See more keywords